Replimune Group, Inc. (REPL) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, Replimune reported revenue of $0. Net income was -$313.9M, or -$3.38 per diluted share. Operating activities generated -$280.3M of cash, leaving -$284.6M of free cash flow. At fiscal year end, Replimune held $332.4M in total assets against $166.2M in total liabilities, including $209.0M of cash and equivalents.
Open the full interactive Replimune financials → Quarterly statements, key ratios, valuation history and price charts.
Replimune Key Stats
| Share Price | $12.11 |
|---|---|
| Market Cap | $1.17B |
| 52-Week Range | $1.70 – $15.98 |
| Shares Outstanding | 96.9 million (basic, 2027 Q1) |
Replimune Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$80.0M | -$118.3M | -$177.1M | -$234.8M | -$261.6M | -$319.9M |
| Pre-Tax Income | -$80.9M | -$118.0M | -$174.0M | -$215.4M | -$246.8M | -$314.5M |
| Income Tax | $0 | $0 | $288,000 | $408,000 | $468,000 | -$551,000 |
| Net Income | -$80.9M | -$118.0M | -$174.3M | -$215.8M | -$247.3M | -$313.9M |
| Diluted EPS | -$1.75 | -$2.26 | -$2.99 | -$3.24 | -$3.07 | -$3.38 |
Replimune Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$83.1M | -$70.9M | -$73.2M | -$69.8M |
| Diluted EPS | -$0.90 | -$0.77 | -$0.79 | -$0.72 |
Replimune Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $182.5M | $105.9M | $146.6M | $74.5M | $111.1M | $209.0M |
| Current Assets | $483.7M | $404.0M | $592.6M | $433.7M | $495.9M | $279.1M |
| Total Assets | $543.1M | $461.2M | $646.6M | $487.7M | $551.3M | $332.4M |
| Current Liabilities | $14.5M | $20.8M | $33.8M | $40.4M | $62.4M | $58.2M |
| Total Long-Term Debt | — | — | $28.6M | $44.8M | $46.4M | $83.3M |
| Total Liabilities | $44.4M | $50.0M | $91.3M | $113.2M | $135.5M | $166.2M |
| Shareholders' Equity | $498.7M | $411.2M | $555.3M | $374.5M | $415.8M | $166.2M |
Replimune Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$61.4M | -$82.2M | -$128.1M | -$185.5M | -$192.2M | -$280.3M |
| Cash From Investing | -$188.8M | -$1.8M | -$142.5M | $97.2M | -$23.8M | $310.8M |
| Cash From Financing | $372.5M | $6.6M | $311.3M | $16.3M | $252.4M | $66.3M |
| Free Cash Flow | -$63.8M | -$84.5M | -$130.3M | -$191.1M | -$198.9M | -$284.6M |
Figures from Replimune's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Replimune financials page for every line item.
Replimune Company Profile
| Ticker | REPL |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Woburn, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | March 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001737953 |
Frequently Asked Questions
What was Replimune's revenue in fiscal 2026?
Replimune (REPL) reported revenue of $0 for fiscal 2026.
What is Replimune's annual revenue history?
Replimune's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Replimune's net income in fiscal 2026?
Replimune reported net income of -$313.9M for fiscal 2026.
What was Replimune's earnings per share (EPS) in fiscal 2026?
Replimune's diluted EPS was -$3.38 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Replimune generate in fiscal 2026?
Replimune generated -$284.6M of free cash flow in fiscal 2026.
What was Replimune's revenue last quarter?
In its most recent reported quarter (2027 Q1), Replimune reported revenue of $0.
How much debt does Replimune have?
Replimune reported $83.3M of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Replimune are outstanding?
Replimune reported a weighted average of 96.9 million basic shares outstanding in 2027 Q1.
What is Replimune's market cap?
Based on its latest closing price, Replimune (REPL) has a market capitalization of about $1.17B.
When does Replimune's fiscal year end?
Replimune's fiscal year end, as registered with the SEC, is March 31.
Where is Replimune headquartered?
Replimune lists its business address in Woburn, Massachusetts in its SEC filings.
Replimune Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →